Sugi Predict

Sugi Predict / Compounds / SCHEMBL4096830

SCHEMBL4096830

SCHEMBL4096830

O=c1[nH]ccc2c3[nH]c(Sc4ccccc4)nc3c3ccc(F)cc3c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 4/20 0.62
▸ JAK2 O60674 17/20 0.58
▸ JAK3 P52333 4/20 0.58
▸ JAK1 P23458 2/20 0.58
▸ TYK2 P29597 2/20 0.58
▸ IKBKB O14920 1/20 0.58
▸ MAPK13 O15264 1/20 0.58
▸ DAPK3 O43293 1/20 0.58
▸ PRKD3 O94806 1/20 0.58
▸ FYN P06241 1/20 0.58
▸ RET P07949 1/20 0.58
▸ HCK P08631 1/20 0.58
▸ PDGFRB P09619 1/20 0.58
▸ PIM1 P11309 1/20 0.58
▸ FGFR1 P11362 1/20 0.58
▸ PDGFRA P16234 1/20 0.58
▸ PRKCA P17252 1/20 0.58
▸ PRKACA P17612 1/20 0.58
▸ FLT1 P17948 1/20 0.58
▸ FGFR2 P21802 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2303002 0.93 CHEK1 (0.56) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL2304834 0.91 JAK2 (0.57) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL3345024 0.90 JAK2 (0.54) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL15389300 0.90 CHEK1 (0.64) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL15389322 0.89 JAK2 (0.53) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL2307006 0.88 JAK2 (0.57) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL2309020 0.88 JAK2 (0.54) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL2307059 0.88 JAK2 (0.56) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL17907478 0.88 CHEK1 (0.58) CHEK1JAK2JAK3JAK1TYK2
SCHEMBL14058026 0.87 JAK2 (0.56) CHEK1JAK2JAK3JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310340-A1 METHOD OF TREATING MUSCULAR DEGRADATION RIGEL PHARMACEUTICALS, INC. (US) 2013-11-21 — — US disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 — — US disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 — — US disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 — — US disclosed
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases INCYTE CORPORATION 2006-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 CHEK1 412/4885JAK2 2/4885JAK3 3/4885
US-20130310340-A1 METHOD OF TREATING MUSCULAR DEGRADATION PYGM, CKMT1A; CKMT1B, SMN1; SMN2 CHEK1 1591/4885JAK2 4729/4885JAK3 4792/4885
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases JAK1, JAK2, JAK3 CHEK1 412/4885JAK2 2/4885JAK3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.